Apollo Global Management, Inc.
—- Market cap
- $78.94B
- Debt
- +$13.36B
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 86% equity / 14% debt
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: APO stock price vs BMRN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BMRN's multiple
Needs BMRN P/E.
Implied fair value · at APO's multiple
Needs APO P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: APO FY 2025 (ended Dec 31, 2025) · BMRN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 86% equity / 14% debt
Capital structure 96% equity / 4% debt · EV / Revenue 3.75x · EV / EBITDA 21.37x
APO carries the larger enterprise value at $92.30B against $12.07B; APO trades on the lower EV / Revenue multiple (2.88x vs 3.75x); APO on the lower EV / EBITDA (16.02x vs 21.37x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
APOLLO GLOBAL MANAGEMENT, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
BIOMARIN PHARMACEUTICAL INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.57x
0.08x
Net debt / EBITDA
Leverage against operating earnings
—
-1.43x
Cash and equivalents
Liquid reserves on the balance sheet
—
$1.31B
Total debt
Interest-bearing obligations outstanding
$13.36B
$505.32M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Blackstone Inc.
APO vs BX
KKR & Co. Inc.
APO vs KKR
Carlyle Group Inc.
APO vs CG
BROOKFIELD Corp /ON/
APO vs BN
VERTEX PHARMACEUTICALS INC / MA
APO vs VRTX
ALNYLAM PHARMACEUTICALS, INC.
APO vs ALNY
Sarepta Therapeutics, Inc.
APO vs SRPT
REGENXBIO Inc.
APO vs RGNX
IONIS PHARMACEUTICALS INC
APO vs IONS
PTC THERAPEUTICS, INC.
APO vs PTCT
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.